Background: Liberation from mechanical ventilation is a major objective in critically ill patients. Various criteria for extubation are used with different success rates. We developed a novel, simple bedside maneuver and index that involves measuring breath-hold duration and forced vital capacity (FVC). We named it the Respiratory Breath Hold Index (RBHI). Methods: We enrolled 225 mechanically ventilated intensive care unit (ICU) patients who were candidates for extubation. At the end of a spontan eous breathing trial (SBT), and just prior to extubation, patients were asked to hold their breath and perform a stalked FVC maneuver. The ability to perform a breath-hold maneuver and its duration were recorded and compared with a standard SBT. Results: 171 patients (76%) were successfully extubated, while 54 patients (24%) failed extubation. A successful SBT alone did not predict extubation, as 80.1% of passed SBT and 81.5% of failed SBT patients were extubated successfully (p = 1.00). However, a higher RBHI, together with the ability to hold breath and breath-hold duration, was highly associated with a successful extubation (p < 0.0001). Logistic regression analysis showed that RBHI over 3 was correlated with higher rates of successful extubation (OR 4.252, p < 0.001). Overall, 89% of patients who passed SBT and were able to hold breath were successfully extubated. (p < 0.0001). Whereas, among patients who passed SBT but failed to hold breath, only 24% were successfully extubated (p < 0.0001). Conclusion: Higher RBHI, together with the ability to hold a breath just prior to extubation in mechanically ventilated patients, is more sensitive and specific, and may be superior to standard SBT in predicting a successful extubation.
Background and Objectives: Admission C-reactive protein (CRP) may assist risk assessment in community-acquired pneumonia (CAP), but its prognostic value remains uncertain. Materials and Methods: In this retrospective single-center database cohort, 134 adults with records classified as CAP/pneumonia during 2019–2023 were evaluated. Admission CRP discrimination for in-hospital mortality was assessed using ROC analysis. Logistic regression was supplemented by Firth bias-reduced sensitivity analyses because only nine deaths occurred. Exploratory Spearman correlations with length of stay (LOS) were repeated among survivors. Results: Nine patients (6.7%) died. Median admission CRP was 274.4 (IQR 198.6–319.0) mg/L in non-survivors versus 126.2 (86.0–177.9) mg/L in survivors (p = 0.0045). Conventional age-adjusted logistic regression yielded an odds ratio (OR) of 5.66 per 100 mg/L CRP increase (95% CI 1.92–16.75; p = 0.0017); the Firth age-adjusted sensitivity analysis yielded OR 4.85 (95% penalized profile-likelihood CI 1.93–15.27; p < 0.001). The ROC AUC was 0.785 (bootstrap 95% CI 0.552–0.973). Among survivors, admission CRP was not significantly correlated with LOS (n = 124; Spearman ρ = 0.083; p = 0.357). Conclusions: Admission CRP remained associated with in-hospital mortality after age adjustment and penalized sensitivity analysis, but limited events, incomplete clinical characterization, and uncertainty in CAP case ascertainment constrain inference. The data-derived threshold and non-standardized serial CRP results are exploratory and require prospective validation.
Sepsis is a life-threatening organ dysfunction syndrome caused by a dysregulated host response to infection that has a high mortality rate. Proprotein convertase subtilisin kexin 9 (PCSK9) is a serine protease secreted by the liver. Its binding to the low-density lipoprotein (LDL) receptor enhances its degradation, causing an increase in LDL levels in the blood. Objectives: Administering a PCSK9 inhibitor leading to an increase in lipid uptake by the liver may positively affect septic patients due to the increased removal of endotoxins. Methods: This preliminary study aimed to examine the safety of PCSK9 inhibitor use in septic and septic shock patients. We treated five septic patients in the intensive care unit with 300 mg of alirocumab following serious adverse events for 28 days. Results: Four of our patients did not experience any adverse events, and all of them survived. One patient died after discharge from the intensive care unit, and this death was presumably not related to the study drug. The patients rapidly recovered from the inflammatory stage of sepsis. Conclusions: Alirocumab appears safe in severe sepsis and septic shock patients. The outcome data are promising. Only a basic safety profile can be assessed based on this pilot study. Further study with a PCSK-9 inhibitor in septic or septic shock patients is required to further determine its benefit in ICU patients.